Cooper N, Ghanima W. Immune Thrombocytopenia. N Engl J Med. 2019;381(10):945–55.

Article  PubMed  Google Scholar 

Semple JW, Rebetz J, Maouia A, Kapur R. An update on the pathophysiology of immune thrombocytopenia. Curr Opin Hematol. 2020;27(6):423–9.

Article  CAS  PubMed  Google Scholar 

Fayyaz A, Igoe A, Kurien BT, Danda D, James JA, Stafford HA, et al. Haematological manifestations of lupus. Lupus Sci Med. 2015;2(1):e000078.

Article  PubMed  PubMed Central  Google Scholar 

Tsukamoto M, Suzuki K, Takeuchi T. Ten-year observation of patients with primary Sjögren’s syndrome: initial presenting characteristics and the associated outcomes. Int J Rheum Dis. 2019;22(5):929–33.

Article  CAS  PubMed  Google Scholar 

Gafter-Gvili A. Current approaches for the diagnosis and management of immune thrombocytopenia. Eur J Intern Med. 2023;108:18–24.

Article  PubMed  Google Scholar 

Chong BH, Ho SJ. Autoimmune thrombocytopenia. J Thromb Haemost. 2005;3(8):1763–72.

Article  CAS  PubMed  Google Scholar 

Liu X-G, Hou Y, Hou M. How we treat primary immune thrombocytopenia in adults. J Hematol Oncol. 2023;16(1):4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Du H, Su W, Su J, Hu J, Wu D, Long W, et al. Sirolimus for the treatment of patients with refractory connective tissue disease-related thrombocytopenia: a pilot study. Rheumatology (Oxford). 2024;63(1):79–84.

Article  CAS  PubMed  Google Scholar 

Provan D, Arnold DM, Bussel JB, Chong BH, Cooper N, Gernsheimer T, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3(22):3780–817.

Article  PubMed  PubMed Central  Google Scholar 

Ghanima W, Khelif A, Waage A, Michel M, Tjønnfjord GE, Romdhan NB, et al. Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet (London England). 2015;385(9978):1653–61.

Article  CAS  PubMed  Google Scholar 

Ogbue OD, Bahaj W, Kewan T, Ahmed R, Dima D, Willimas N, et al. Splenectomy outcomes in immune cytopenias: treatment outcomes and determinants of response. J Intern Med. 2024;295(2):229–41.

Article  CAS  PubMed  Google Scholar 

Miltiadous OHM, Bussel JB. Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment. Blood. 2020;135(7):472–90.

Article  PubMed  PubMed Central  Google Scholar 

Markham A, Avatrombopag. Rev Thrombocytopenia Drugs. 2021;81(16):1905–13.

CAS  Google Scholar 

Li W, Wang D, Ma L, Zhu Y, Wang F, Hua B, et al. Eltrombopag in severe immune thrombocytopenia secondary to connective tissue disease: a report of 17 patients and literature review. Clin Rheumatol. 2023;42(5):1451–7.

Article  PubMed  Google Scholar 

Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for systemic Lupus Erythematosus. Arthritis Rheumatol. 2019;71(9):1400–12.

Article  PubMed  PubMed Central  Google Scholar 

Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, et al. 2016 American College of Rheumatology/European League against Rheumatism Classification Criteria for Primary Sjögren’s syndrome: a Consensus and Data-Driven Methodology Involving Three International Patient cohorts. Arthritis Rheumatol. 2016;69(1):35–45.

Article  PubMed  PubMed Central  Google Scholar 

Akiyama M, Yasuoka H, Yoshimoto K, Takeuchi T. Interleukin-4 contributes to the shift of balance of IgG subclasses toward IgG4 in IgG4-related disease. Cytokine. 2018;110:416–9.

Article  CAS  PubMed  Google Scholar 

Mosca M, Neri R, Bombardieri S. Undifferentiated connective tissue diseases (UCTD): a review of the literature and a proposal for preliminary classification criteria. Clin Exp Rheumatol. 1999;17(5):615–20.

CAS  PubMed  Google Scholar 

Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295–306.

Article  CAS  PubMed  Google Scholar 

Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69(9):1580–8.

Article  PubMed  Google Scholar 

Yoo J, Kim HJ, Ahn SS, Jung SM, Song JJ, Park Y-B, et al. The utility of the ACR/EULAR 2017 provisional classification criteria for granulomatosis with polyangiitis in Korean patients with antineutrophil cytoplasmic antibody-associated vasculitis. Clin Exp Rheumatol. 2018;36(Suppl 111):85–7.

PubMed  Google Scholar 

Ghanima W, Cooper N, Rodeghiero F, Godeau B, Bussel JB. Thrombopoietin receptor agonists: ten years later. Haematologica. 2019;104(6):1112–23.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cooper N, Scully M, Percy C, Nicolson PLR, Lowe G, Bagot CN et al. Real-world use of thrombopoietin receptor agonists for the management of immune thrombocytopenia in adult patients in the United Kingdom: results from the TRAIT study. Br J Haematol. 2024.

Gilreath J, Lo M, Bubalo J. Thrombopoietin receptor agonists (TPO-RAs): drug class considerations for pharmacists. Drugs. 2021;81(11):1285–305.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shobha V, Sanil S, Roongta R, Eltrombopag. Efficacy and safety in Steroid Refractory Lupus-Associated Immune Thrombocytopenia. J Clin Rheumatol. 2020;26(7):274–8.

Article  PubMed  Google Scholar 

Wang J, Dai M, Fu Q, Chen S. Eltrombopag for the treatment of refractory thrombocytopenia associated with connective tissue disease. Sci Rep. 2021;11(1):5459.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xu L, Zhang Y, Lin N, Song X, Dai Q. Eltrombopag improves refractory thrombocytopenia in patients with Sjögren’s syndrome. Sci Prog. 2022;105(2):368504221102786.

Article  CAS  PubMed  Google Scholar 

Sun L, Huang X, Wang J, Yuan C, Zhao H, Li D et al. Eltrombopag plus Diacerein vs. eltrombopag in patients with ITP: a multicenter, randomized, open-label, phase 2 trial. Blood. 2024.

Cooper N, Scully M, Percy C, Nicolson PLR, Lowe G, Bagot CN, et al. Real-world use of thrombopoietin receptor agonists for the management of immune thrombocytopenia in adult patients in the United Kingdom: results from the TRAIT study. Br J Haematol. 2024;204(6):2442–52.

Article  CAS  PubMed  Google Scholar 

Molander V, Bower H, Frisell T, Askling J. Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden. Ann Rheum Dis. 2021;80(2):169–75.

Article  CAS  PubMed  Google Scholar 

van Dijk WEM, Brandwijk ON, Heitink-Polle KMJ, Schutgens REG, van Galen KPM, Urbanus RT. Hemostatic changes by thrombopoietin-receptor agonists in immune thrombocytopenia patients. Blood Rev. 2021;47:100774.

Article  PubMed  Google Scholar 

Audia S, Mahévas M, Samson M, Godeau B, Bonnotte B. Pathogenesis of immune thrombocytopenia. Autoimmun Rev. 2017;16(6):620–32.

Article  CAS  PubMed  Google Scholar 

Liu Y, Chen S, Sun Y, Lin Q, Liao X, Zhang J, et al. Clinical characteristics of immune thrombocytopenia associated with autoimmune disease: a retrospective study. Med (Baltim). 2016;95(50):e5565.

Article  CAS  Google Scholar